Benzene Ring Containing Patents (Class 514/741)
-
Patent number: 7566740Abstract: A method of treating mucositis in immunocompromised patients is disclosed which is based on contacting the affected area with an amount of composition which comprises triclosan and a cationic antibacterial agent in amounts which are effective to alleviate the symptoms of mucositis.Type: GrantFiled: December 12, 2002Date of Patent: July 28, 2009Assignee: BML Pharmaceuticals, Inc.Inventor: Barry Libin
-
Patent number: 7560098Abstract: Polymers containing one or more crylene moieties attached to the polymer backbone, sunscreen compositions including a mixture of a photoactive compound and a polymer containing one or more crylene moieties attached to the polymer backbone are described herein. Also disclosed are methods for stabilizing a sunscreen composition and methods of filtering out ultra-violet light from a substrate by the addition of one or more of the foregoing polymers, and methods of waterproofing and forming a film with one or more of the foregoing polymer are described herein.Type: GrantFiled: October 15, 2004Date of Patent: July 14, 2009Assignee: Hallstar Innovations Corp.Inventors: Craig A. Bonda, Anna B. Pavlovic
-
Patent number: 7550134Abstract: Polymers containing one or more fluorene moieties attached to the polymer backbone, sunscreen compositions including a mixture of a photoactive compound and a polymer containing one or more fluorene moieties attached to the polymer backbone are described herein. Also disclosed are methods for stabilizing a sunscreen composition and methods of filtering out ultra-violet light from a substrate by the addition of one or more of the foregoing polymers, and methods of waterproofing and forming a film with one or more of the foregoing polymer are described herein.Type: GrantFiled: October 15, 2004Date of Patent: June 23, 2009Assignee: Hallstar Innovations Corp.Inventors: Craig A. Bonda, Anna B. Pavlovic
-
Patent number: 7514470Abstract: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.Type: GrantFiled: March 3, 2005Date of Patent: April 7, 2009Assignee: SmithKline Beecham CorporationInventors: Philip Stewart Turnbull, Rodolfo Cadilla, David John Cowan, Andrew Lamont Larkin, Istvan Kaldor, Eugene Lee Stewart
-
Publication number: 20080318881Abstract: The present invention includes a fast-drying liquid composition comprising at least one fungicide and at least one insecticide. The present invention further includes a method for treating plant propagation materials, especially cut seeds, including tubers, against pests, a method for promoting suberization in cut seeds, a method for decreasing the drying time of a liquid pesticide on cut seeds, and a method for selectively loading a pesticide onto the skin side of a cut seed.Type: ApplicationFiled: June 28, 2006Publication date: December 25, 2008Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Marlene Torrent-Parker, Kiran Shetty
-
Patent number: 7432289Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.Type: GrantFiled: October 16, 2002Date of Patent: October 7, 2008Assignee: Glaxo Group LimitedInventors: Richard Martyn Angell, Nicola Mary Aston, Paul Bamborough, Mark James Bamford, George Stuart Cockerill, Stephen Sean Flack, Dramane Ibrahim Lainé, Suzanne Joy Merrick, Kathryn Jane Smith, Ann Louise Walker
-
Patent number: 7432307Abstract: Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.Type: GrantFiled: November 4, 2005Date of Patent: October 7, 2008Assignee: Sirion Therapeutics, Inc.Inventors: Nathan L. Mata, Kenneth Widder, Jay Lichter
-
Publication number: 20080227869Abstract: A method for the prophylaxis or treatment of analgesic, hemostatic, antipruritic, antiussive or antiasthmatic action including administrating an effective prophylaxis or treatment amount of at least one compound of Formula I as the active ingredient, pharmaceutical carrier and/or recipient, wherein, A is one, two or three nitro groups, at 1, 3, and/or 5 position on the benzene ring; R is one, two or three linear or branched C1-6 alkyl groups, at 2, 4 and/or 6 position on the benzene ring.Type: ApplicationFiled: April 23, 2008Publication date: September 18, 2008Inventors: Tewa Men, Yangyang Men
-
Publication number: 20080207713Abstract: The present invention is directed to compounds, combinations, compositions and methods for enhancing nitric oxide (NO) delivery to target sites, and in particular to muscle, both normal and dystrophic. Enhanced NO delivery according to the present invention may be achieved by using a combination of a muscle relaxant and an NO donor compound, or by using a compound of the invention: formula (I) wherein R1 is H, halo, C1-6 alkoxy or C1-6 alkyl; R2 is H, NO2 or C(O)NH2; R3 is H, NO2 or C(O)NH2; and at least one of R2 and R3 is NO2; or a pharmaceutically acceptable salt of the compound.Type: ApplicationFiled: June 8, 2006Publication date: August 28, 2008Inventors: Gu-Qi Wang, Frank J Burczynski, Judith E Anderson
-
Patent number: 7407648Abstract: The use is described of merocyanine derivatives of formula (1), wherein R1 and R2 are each independently of the other hydrogen; C1-C22alkyl; cyclo-C3C8alkyl; or unsubstituted or C1-C5alkyl- or C1-C5alkoxy-substituted C6-C20aryl; orl; or R1 and R2 together with the nitrogen atom linking them form a —(CH2)m— ring which is uninterrupted or, interrupted by —O— or by —NH—; R3 is a cyano group; —COOR5; —CONHR5; —COR5; or —SO2R5; R4 is a cyano group; —COOR6; —CONHR6; —COR6; or —SO2R6; R5 and R6 are each independently of the other C1-C22alkyl; or unsubstituted or C1-C5alkyl substituted C6-C20aryl; or R3 and R4 together or R5 and R6 together form in a 5- to 7-membered, monocyclic, carbocyclic or heterocyclic ring; Z1, and Z2 are each independently of the other a —(CH2)n— group which is uninterrupted or interrupted by —O—, —S—, or by —NR7—, and/or is unsubstituted or substituted by C1-C5alkyl; R7 is (ClC5alkyl; 1 is from 1 to 4; m is from 1 to 7; n is from 1 to 4; when n=2, R1, R5 or R6 is a bivalent alkyl group; or R1Type: GrantFiled: July 1, 2003Date of Patent: August 5, 2008Assignee: Ciba Specialty Chemicals Corp.Inventors: Barbara Wagner, Thomas Ehlis, Kai Eichin
-
Patent number: 7378409Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.Type: GrantFiled: August 19, 2004Date of Patent: May 27, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Percy H. Carter, Robert J. Cherney, Douglas G. Batt, Gregory D. Brown, John V. Duncia, Daniel S. Gardner, Michael G. Yang
-
Patent number: 7358226Abstract: Methods, compositions and apparatus for localized delivery of compounds are provided. In certain embodiments, radiation force is used to direct carriers to a target site, and additional radiation is used to fragment the localized carriers, releasing associate compounds. Ultrasound radiation is preferred as the source for radiation force and for fragmentation. Also encompassed are embodiments in which targeting and fragmentations are combined with imaging of the treatment site. Alternate embodiments are disclosed in which compounds are locally delivered without use of carriers.Type: GrantFiled: August 26, 2004Date of Patent: April 15, 2008Assignee: The Regents of the University of CaliforniaInventors: Paul Dayton, Katherine W. Ferrara, Michaelann Shortencarier, Susannah Bloch
-
Publication number: 20080057098Abstract: The present invention relates to new use of inhibitors of bcl-2/bcl-XI family of anti-apoptotic compounds for the treatment of post-angioplasty restenosis and in-stent restenosis. Small molecules of Bcl inhibitors are incorporated into a stent, typically by a fine polymeric coating over the metal, which would be placed during angioplasty of occluded blood vessels, to act on fibroproliferative in-growth. Hollow organs such as urethras, Fallopian tubes and vascular access grafts could be treated in a similar manner to prevent their closure due to fibrosis. Other iatrogenic fibrosis such as adhesions after surgery could also be blocked by this therapy.Type: ApplicationFiled: August 31, 2007Publication date: March 6, 2008Inventors: Timothy A. McCaffrey, Zhaoqing Yang, Dmitri Gagarin
-
Publication number: 20080050434Abstract: Pharmaceutical composition for topical administration comprising of at least one active ingredient, its salts, esters, hydrates or derivatives; a gelator system consisting of a fiend of surfactants, a solvent system comprising at least one oily component; an aqueous phase; optionally containing one or more stabilizing agent; and other pharmaceutically acceptable excipients; and process for preparing such compositions are provided. Also provided is a method for the management/treatment of fungal, bacterial or microbial infections, inflammations, autoimmune conditions, or hormonal disorders which comprises administering a pharmaceutically effective amount of such pharmaceutical composition to a subject in need of such treatment. The compositions of the present invention are non-greasy and easily water washable, and provides an enhanced localization of hydrophobic and/or amphiphilic active ingredients on the skin.Type: ApplicationFiled: March 17, 2005Publication date: February 28, 2008Inventors: Rajesh Jain, Kour Chand, Sukhjeet Singh, Vaibhav Sihorkar
-
Publication number: 20080033027Abstract: The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and methods of making and using them. The invention provides compositions and therapies comprising use of a beta adrenergic antagonist (also called “beta blockers”, e.g., propranolol) in combination with an anti-inflammatory agent, e.g., a nonsteroidal anti-inflammatory drug (NSAID), an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), an anabolic steroid, a natural oil or fatty acid or any combination thereof.Type: ApplicationFiled: July 28, 2006Publication date: February 7, 2008Applicant: VICUS THERAPEUTICS SPE 1, LLCInventors: Newell Bascomb, John Maki, Frederic S. Young
-
Patent number: 7316738Abstract: A method of milling chlorothalonil to form a sub-micron product having a narrow particle size distribution is presented. The milling involves wet milling of the chlorothalonil with high density milling media having a diameter between 0.1 mm and 0.8 mm, preferably between 0.2 mm and 0.7 mm, and a density equal to or greater than 3.8 g/cc, preferably greater than 5.5 g/cc, in a ball mill using between about 40% and 80% loading of the mill volume with milling media, and having the chlorothalonil suspended in an aqueous milling liquid which comprises one or more surface active agents. The milling speed is preferably high, for example from about 1000 rpm to about 4000 rpm. The milled product can be used in foliar applications at a lower effective dosage than prior art formulations, can be used in improved antifouling paint formulations, and can be used in new applications such as the direct injection of solid chlorothalonil particulates in wood to act as a long lasting wood preservative.Type: GrantFiled: October 12, 2004Date of Patent: January 8, 2008Assignee: Phibro-Tech, Inc.Inventors: Hugh W. Richardson, Robert L. Hodge
-
Publication number: 20070219278Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: February 28, 2007Publication date: September 20, 2007Inventors: Daniel D. Long, Timothy J. Church, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades, Priscilla M. Van Dyke, Sean Dalziel, Leticia Maria Preza
-
Patent number: 7268161Abstract: The comprehensive pharmacologic therapy for treatment of obesity including Cysteine is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, Cysteine, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.Type: GrantFiled: July 6, 2004Date of Patent: September 11, 2007Inventor: Martin C. Hinz
-
Patent number: 7241741Abstract: The present invention provides methods for the treatment of respiratory tract mucositis in individuals in need of such treatment, the method comprising the systemic administration to the individual of therapeutically effective amounts of at least one anti-fungal agent and at least one anti-bacterial agent, wherein the treatment does not involve the cessation of use of emollients by the individual. The present invention also provides compositions suitable for use in the treatment of respiratory tract mucositis.Type: GrantFiled: July 23, 2004Date of Patent: July 10, 2007Assignee: Atopic Pty. Ltd.Inventor: Thomas J. Borody
-
Patent number: 7232847Abstract: The invention relates to 4-hydroxymethyl-1-aryl-cyclohexylamine compounds, methods for their production, pharmaceutical formulations containing such compounds and the use of 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives for producing medicines which are useful, for example for treating pain. Related methods of treatment are also provided.Type: GrantFiled: May 11, 2005Date of Patent: June 19, 2007Assignee: Gruenenthal GmbHInventors: Bernd Sundermann, Hans Schick, Claudia Hinze
-
Patent number: 7164034Abstract: This invention relates to a method of treating a disorder selected from OCD, agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, PTSD, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia by administering a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl; and R2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The invention also relates to a method of treating the above disorders by administering the compound (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid.Type: GrantFiled: December 12, 2003Date of Patent: January 16, 2007Assignee: Pfizer Inc.Inventors: David James Dooley, Charles Price Taylor, Jr., Andrew John Thorpe, David Juergen Wustrow
-
Patent number: 7041704Abstract: The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat a gastrointestinal tract disorders, particularly inflammatory bowel disorders and irritable bowel syndrome.Type: GrantFiled: February 11, 2005Date of Patent: May 9, 2006Assignee: Dynogen Pharmaceuticals, Inc.Inventors: Edward C. Burgard, Steven B. Landau, Matthew Oliver Fraser
-
Patent number: 7012100Abstract: Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.Type: GrantFiled: June 4, 2002Date of Patent: March 14, 2006Assignee: Avolix Pharmaceuticals, Inc.Inventors: David L. Edwards, Michael E. Berens, Christian Beaudry
-
Patent number: 6878750Abstract: This invention describes the new benzocycloheptenes of general formula I in which R1, R2 and SK have the meanings that are indicated in the description. The new compounds have selective estrogenic activity on bones and are suitable for the production of pharmaceutical agents, especially for prophylaxis and therapy of osteoporosis.Type: GrantFiled: September 11, 2002Date of Patent: April 12, 2005Assignee: Schering AGInventors: Rolf Bohlmann, Jorg Kroll, Hermann Kuenzer, Christa Hegele-Hartung, Monika Lessl, Rosemarie Lichtner, Yukishige Nishino
-
Patent number: 6759437Abstract: The comprehensive pharmacologic therapy for treatment of obesity including Cysteine is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, Cysteine, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.Type: GrantFiled: September 6, 2001Date of Patent: July 6, 2004Inventor: Martin C. Hinz
-
Patent number: 6730686Abstract: The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions. The instant invention also teaches new methods to treat or prevent oxidative modification of proteins, including low density lipoproteins, to treat or prevent lipid peroxidation, and to treat or prevent atherosclerosis, comprising administering an amount effective of one of the compounds of the invention to treat or prevent the disorder.Type: GrantFiled: October 8, 1999Date of Patent: May 4, 2004Assignees: Kansas University Medical Center, University of South CarolinaInventors: John W. Baynes, Joelle Onorato, Suzanne Thorpe, Raja Khalifah, Billy G. Hudson
-
Patent number: 6656960Abstract: A method for indirectly stimulating a vagus nerve of a patient includes the steps of positioning one or more electrodes in the vicinity of the vagus nerve and then actuating the electrode(s) to create an electrical field for stimulating the vagus nerve. Disclosed embodiments include positioning one or more electrodes in the esophagus, trachea, or jugular vein, on the neck of the patient, and combinations thereof.Type: GrantFiled: January 17, 2002Date of Patent: December 2, 2003Assignee: Emory UniversityInventor: John D. Puskas
-
Patent number: 6653353Abstract: Cosmetic or personal care compositions comprise: a hair styling polymer having one or more groups selected from acidic functional groups, anionic groups derived from the acidic functional groups or a mixture of said groups; a partially or fully fluorinated compound having one or more groups selected from amino groups, acid salts of the amino groups or a mixture of said groups, wherein the partially or fully fluorinated compound comprises an aromatic ring; and a cosmetically acceptable diluent or carrier. The compositions are particularly effective under high humidity conditions.Type: GrantFiled: March 13, 2002Date of Patent: November 25, 2003Assignee: Unilever Home & Personal Care USA, division of Conopco, Inc.Inventors: Gerald Adams, Ezat Khoshdel
-
Patent number: 6642243Abstract: This invention is a safe and effective composition and method for treating acute migraine attacks using pseudoephedrine, acetaminophen, and other agents in an orally administrated form to alleviate the pain and cluster of symptoms characteristic of migraine attacks such as nausea, photophobia, phonophobia, and functional disabilities as well as the prodrome phase of a migraine attack.Type: GrantFiled: June 14, 2000Date of Patent: November 4, 2003Inventor: Ashkan Imanzahrai
-
Patent number: 6642398Abstract: The instant invention is a series of novel mono- and disubstituted 3-propyl gamma aminobutyric acids of Formula I The compounds are useful as therapeutic agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, arthritis, sleep disorders, IBS, and gastric damage. Methods of preparing the compounds and useful intermediates are also part of the invention.Type: GrantFiled: December 20, 2002Date of Patent: November 4, 2003Assignee: Warner-Lambert CompanyInventors: Thomas Richard Belliotti, Justin Stephen Bryans, Ihoezo Victor Ekhato, Augustine Tobi Osuma, Robert Michael Schelkun, Jacob Bradley Schwarz, Andrew John Thorpe, Lawrence David Wise, David Juergen Wustrow, Po-Wai Yuen
-
Patent number: 6627177Abstract: The present invention concerns an improved optical method and optical sensing device for determining the levels of polyhydroxyl-substituted organic molecules in vivo in aqueous media. Specifically, a dye is combined with a conjugated nitrogen-containing heterocyclic aromatic boronic acid-substituted bis-onium compound in the presence of a sugar, such as fructose or glucose. The viologens are preferred as the aromatic conjugated nitrogen-containing boronic acid substituted compounds. The method is useful to determine sugar levels in a human being.Type: GrantFiled: December 5, 2000Date of Patent: September 30, 2003Assignee: The Regents of the University of CaliforniaInventors: Bakthan Singaram, Ritchie A. Wessling
-
Publication number: 20030072825Abstract: Dinitrohalogenated compounds may be utilized by injection in certain clinical situations to provide a possibility of long term control of human malignancy. In some of those settings no other treatment offers such potential. Preparation methods may include acetone, olive oil, microsomes, liposomes, or combinations thereof. Optimum pretreatment management, dosing and injection techniques are described.Type: ApplicationFiled: October 17, 2001Publication date: April 17, 2003Inventor: Max Harry Cohen
-
Patent number: 6503953Abstract: A method for treating an atopic disorder in a patient is provided. The method comprises administering to the patient an effective amount of at least one of an antifungal and an antibiotic over a period of time. The method further comprises reducing over the period of time the application of emollients to the patient by at least about 50%, relative to the amount of application of emollients prior to treatment.Type: GrantFiled: July 26, 2001Date of Patent: January 7, 2003Assignee: Atopic Pty Ltd.Inventor: John K. Vyden
-
Patent number: 6498191Abstract: The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus, Parkinson's Disease, neuronal and cardiac ischemia, Huntington's disease and stroke.Type: GrantFiled: December 7, 2000Date of Patent: December 24, 2002Assignee: MitoKorInventors: Soumitra S. Ghosh, Scott W. Miller, Robert E. Davis, Walter H. Moos
-
Patent number: 6495607Abstract: Benzocycloheptenes of general formula I in which R1, R2 and Y have the meanings indicated herein, have antiestrogenic activity on and are suitable for the production of pharmaceutical agents, especially for prophylaxis and therapy of osteoporosis.Type: GrantFiled: July 19, 1999Date of Patent: December 17, 2002Assignee: Schering AGInventors: Rolf Bohlmann, Jorg Kroll, Hermann Kuenzer, Christa Hegele-Hartung, Monika Lessl, Rosemarie Lichtner, Yukishige Nishino
-
Patent number: 6495715Abstract: The present invention provides compounds that block calcium channels having the Formula I shown below. The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of Formula I.Type: GrantFiled: January 25, 2001Date of Patent: December 17, 2002Assignee: Warner-Lambert CompanyInventors: Lain-Yen Hu, Michael Francis Rafferty, Todd Robert Ryder
-
Patent number: 6495567Abstract: A method and product for treating and preventing diarrhea and scours is provided. The method involves treating a subject who has diarrhea, or scours, or is at risk of getting diarrhea or scours with an aromatic compound of the invention. The products of the invention are a veterinary preparation of the aromatic compound of the invention and an anti-scours agent, and a pharmaceutical preparation of the aromatic compound of the invention and an anti-diarrheal agent.Type: GrantFiled: September 23, 1998Date of Patent: December 17, 2002Assignees: Beth Israel Deaconess Medical Center, Children's Medical Center CorporationInventors: Wayne I. Lencer, Carlo Brugnara, Seth Alper
-
Patent number: 6486209Abstract: Use of a compound of formula I wherein R1 is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and each of R2, R3, R4 and R5, independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form, in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of acute rejection in a xenograft transplant recipient.Type: GrantFiled: July 3, 2001Date of Patent: November 26, 2002Assignee: Novartis AGInventors: Sylvain Cottens, Robert Paul Hof, Roland Wenger
-
Patent number: 6472411Abstract: The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions.Type: GrantFiled: November 28, 2000Date of Patent: October 29, 2002Assignee: University of Kansas Medical CenterInventors: Billy G. Hudson, Parvin Todd, Raja Gabriel Khalifah, Aaron Ashley Booth
-
Patent number: 6462091Abstract: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an HMG CoA reductase inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.Type: GrantFiled: December 17, 1999Date of Patent: October 8, 2002Assignee: G.D. Searle & Co.Inventors: Bradley T. Keller, James A. Sikorski, Kevin C. Glenn, Daniel T. Connolly, Mark E. Smith
-
Patent number: 6458851Abstract: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an ileal bile acid transport inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.Type: GrantFiled: December 17, 1999Date of Patent: October 1, 2002Assignee: G. D. Searle, LLCInventors: Bradley T. Keller, James A. Sikorski, Kevin C. Glenn, Daniel T. Connolly, Mark E. Smith, Joseph R. Schuh
-
Patent number: 6458850Abstract: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include a fibric acid derivative combined with a cholesteryl ester transfer protein (CETP) inhibitor.Type: GrantFiled: December 17, 1999Date of Patent: October 1, 2002Assignee: G.D. Searle, LLCInventors: James A. Sikorski, Kevin C. Glenn
-
Patent number: 6444699Abstract: An ascorbic acid-based composition and related method for the treatment of aging or photo-damaged skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0% (w/v) ascorbic acid and may advantageously be formulated to have a pH above 3.5. Generally, the composition also includes non-toxic zinc salt, tyrosine compound, and/or pharmaceutically acceptable carrier. In addition, the composition may include an anti-inflammatory compound, such as aminosugar and/or sulfur-containing anti-inflammatory compound. The topical composition may be in the form of a serum, a hydrophilic lotion, an ointment, a cream, or a gel.Type: GrantFiled: December 7, 2000Date of Patent: September 3, 2002Assignee: Bioderm, Inc.Inventor: Lorraine Faxon Meisner
-
Patent number: 6433011Abstract: A method is provided for inhibiting the development of colon tumorigenesis in a mammal by administering to the mammal a pharmacologically effective amount of an isothiocyanate selected from the group consisting of sulforaphane and phenethyl isothiocyanate.Type: GrantFiled: March 8, 2000Date of Patent: August 13, 2002Assignee: American Health FoundationInventors: Fung-Lung Chung, Bandaru Reddy, C. Clifford Conaway
-
Patent number: 6433023Abstract: This invention is directed to a composition comprising 4-chloro-3,6-dinitrobenzotrifluoride and related compounds and method for using it to treat infections caused by organisms that have microtubules.Type: GrantFiled: March 26, 1998Date of Patent: August 13, 2002Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Heather Callahan, Colleen Kelley, Max Grogl, Brian G. Schuster
-
Patent number: 6429217Abstract: Controlled cessation of heart beat during coronary bypass surgery and other cardiac surgeries on a beating heart improves surgical technique, and is achieved typically by electrical stimulation of the vagus nerve and administration of a combination of drugs.Type: GrantFiled: November 20, 2000Date of Patent: August 6, 2002Assignee: Emory UniversityInventor: John D. Puskas
-
Publication number: 20020090732Abstract: The present invention relates to an agent for the expression of long-term potentiation of synaptic transmission, which contains a compound having a brain somatostatin activation property as an active ingredient and to a screening method of an agent for the expression of long-term potentiation of synaptic transmission, which uses a somatostatin releasing property as an index The present invention is useful for the prophylaxis and/or treatment of cerebral diseases of dementia, amnesia, manic-depressive psychosis, schizophrenia, Parkinson's disease, psychosomatic disease and the like.Type: ApplicationFiled: January 10, 2002Publication date: July 11, 2002Applicant: Fujisawa Pharmaceutical Co. Ltd.Inventors: Nobuya Matsuoka, Masamichi Satoh
-
Patent number: 6414033Abstract: A method for delivery of pharmaceutically effective amounts of drugs and therapeutic ions is disclosed. More particularly, a method of formulating a dosage form that will move drugs, pro-drugs or therapeutic ions in either cationic or anionic form between voltaic cell compartments of the human body, such as from the mouth into the naso-pharyngeal area or into the lung is set forth. The method utilizes naturally occurring concentration gradients in the form of concentration cells, which are constituents of the anatomy. A dosage formulation designed in consideration of naturally occurring pH gradients, i.e., Teorell-Meyer gradients, and a method of treatment by delivering a pharmaceutically effective amount of ions or drugs using the formulation designed in consideration of Teorell-Meyer gradients, is also described.Type: GrantFiled: September 20, 1999Date of Patent: July 2, 2002Assignee: Gelsus Research and Consulting, Inc.Inventor: Nicholas Sceusa
-
Patent number: 6403657Abstract: The comprehensive pharmacologic therapy for treatment of obesity is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.Type: GrantFiled: October 5, 1999Date of Patent: June 11, 2002Inventor: Martin C. Hinz
-
Publication number: 20020068765Abstract: This invention describes the new benzocycloheptenes of general formula I 1Type: ApplicationFiled: July 19, 1999Publication date: June 6, 2002Inventors: ROLF BOHLMANN, JORG KROLL, HERMANN KUENZER, CHRISTA HEGELE-HARTUNG, MONIKA LESSL, ROSEMARIE LICHTNER, YUKISHIGE NISHINO